A large-scale observational study identified that adjuvant therapy after esophagectomy is beneficial primarily for patients with node-positive squamous cell carcinoma and specific advanced adenocarcinoma stages. Patients with adenocarcinoma experienced survival benefits mainly in cases with PT4 or PTanyN3M0 cancers, while a decrement was noted in less severe cases. For squamous cell carcinoma, survival improvements ranged from 4 to 21 months, highlighting the need for tailored treatment guidelines based on cancer type and stage.
Journal Article by Raja S, Rice TW (…) Ishwaran H et 7 al. in Ann Surg Open
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.